La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

JCR Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

JCR Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 10.7% e 2.2% all'anno. Si prevede che l'EPS crescerà di 10.7% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 8.1% in 3 anni.

Informazioni chiave

10.7%

Tasso di crescita degli utili

10.7%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	13.9%
Tasso di crescita dei ricavi	2.2%
Rendimento futuro del capitale proprio	8.1%
Copertura analitica	Good
Ultimo aggiornamento	12 Aug 2024

Aggiornamenti recenti sulla crescita futura

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

Aug 03

Recent updates

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Aug 09

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

Aug 03

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

Jul 26

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Jul 12

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

May 22

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Mar 18

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Feb 29

Previsioni di crescita degli utili e dei ricavi

TSE:4552 - Stime future degli analisti e dati finanziari passati (JPY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2027	41,825	5,169	4,181	N/A	7
3/31/2026	41,259	4,723	7,283	N/A	7
3/31/2025	41,563	4,912	9,780	N/A	7
6/30/2024	40,208	4,098	N/A	N/A	N/A
3/31/2024	42,871	5,507	7,217	9,312	N/A
12/31/2023	41,365	5,364	N/A	N/A	N/A
9/30/2023	43,034	8,063	-9,017	-952	N/A
6/30/2023	35,545	4,014	N/A	N/A	N/A
3/31/2023	34,343	3,772	-14,060	-5,500	N/A
12/31/2022	37,508	5,154	N/A	N/A	N/A
9/30/2022	38,280	6,235	4,857	13,009	N/A
6/30/2022	50,875	14,343	N/A	N/A	N/A
3/31/2022	51,082	14,507	-2,044	9,289	N/A
12/31/2021	50,931	16,549	N/A	N/A	N/A
9/30/2021	47,517	14,899	-6,495	1,362	N/A
6/30/2021	34,717	7,657	N/A	N/A	N/A
3/31/2021	30,085	6,892	2,814	10,341	N/A
12/31/2020	26,128	4,137	N/A	N/A	N/A
9/30/2020	24,496	2,983	1,040	6,210	N/A
6/30/2020	24,807	3,076	N/A	N/A	N/A
3/31/2020	24,781	2,678	89	4,927	N/A
12/31/2019	25,709	3,653	N/A	N/A	N/A
9/30/2019	24,121	3,260	11	4,482	N/A
6/30/2019	23,638	3,802	N/A	N/A	N/A
3/31/2019	23,160	3,715	3,010	3,905	N/A
12/31/2018	20,874	2,454	N/A	N/A	N/A
9/30/2018	20,682	2,566	2,710	3,675	N/A
6/30/2018	20,885	2,857	N/A	N/A	N/A
3/31/2018	20,594	3,070	N/A	3,133	N/A
12/31/2017	20,233	2,930	N/A	N/A	N/A
9/30/2017	19,738	2,722	N/A	2,572	N/A
6/30/2017	18,670	2,079	N/A	N/A	N/A
3/31/2017	18,085	1,863	N/A	2,651	N/A
12/31/2016	17,483	1,668	N/A	N/A	N/A
9/30/2016	17,190	1,751	N/A	1,017	N/A
6/30/2016	17,091	1,620	N/A	N/A	N/A
3/31/2016	17,438	1,789	N/A	2,201	N/A
12/31/2015	17,594	2,299	N/A	N/A	N/A
9/30/2015	17,482	2,281	N/A	2,853	N/A
6/30/2015	17,192	1,861	N/A	N/A	N/A
3/31/2015	16,855	1,682	N/A	499	N/A
12/31/2014	16,380	1,066	N/A	N/A	N/A
9/30/2014	16,516	1,319	N/A	2,795	N/A
6/30/2014	16,117	1,316	N/A	N/A	N/A
3/31/2014	15,705	1,296	N/A	4,565	N/A
12/31/2013	15,669	1,517	N/A	N/A	N/A
9/30/2013	14,818	958	N/A	3,007	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 4552 ( 10.7% all'anno) è superiore al tasso di risparmio ( 0.3% ).

Guadagni vs Mercato: Si prevede che gli utili di 4552 ( 10.7% all'anno) cresceranno più rapidamente del mercato JP ( 8.5% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 4552 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 4552 ( 2.2% all'anno) crescerà più lentamente rispetto al mercato JP ( 4.3% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 4552 ( 2.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 4552 sarà basso tra 3 anni ( 8.1 %).

JCR Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

Consensus EPS estimates fall by 17%

Price target decreased by 10% to JP¥1,314

Price target decreased by 10% to JP¥1,657

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Consensus EPS estimates increase by 13%

Recent updates

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Investor sentiment deteriorates as stock falls 17%

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

First quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd Announces Discontinuation of TEMCELL HS Inj. Expanded Indication Development for Neonatal Hypoxic Ischemic Encephalopathy

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Final dividend of JP¥10.00 announced

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

Consensus EPS estimates fall by 17%

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Price target decreased by 10% to JP¥1,314

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Investor sentiment deteriorates as stock falls 22%

Full year 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index (USD)

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Now 22% overvalued

JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Price target decreased by 10% to JP¥1,657

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Jan 26, 2024

New major risk - Share price stability

JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)

Upcoming dividend of JP¥10.00 per share at 1.5% yield

Investor sentiment improves as stock rises 18%

PHC IVD and JCR Announce GROWJECTOR® Duo

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Oct 25, 2023

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Consensus EPS estimates increase by 13%

First quarter 2024 earnings released: EPS: JP¥12.90 (vs JP¥11.05 in 1Q 2023)

Price target decreased by 7.4% to JP¥1,859

JCR Receives Approval to Start Global Phase I/II Clinical Trial for JR-441 for the Treatment of Mucopolysaccharidosis Type III A (MPS IIIA)

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Receives an Approval for Expanded Indication of Growject®? in Short Stature Due to SHOX-Deficiency

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 20%

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Jul 26, 2023

Consensus EPS estimates fall by 24%

Full year 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued after recent price drop

Consensus revenue estimates fall by 17%

Upcoming dividend of JP¥10.00 per share at 1.3% yield

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

JCR Pharmaceuticals Co., Ltd. to Present Phase I/II Clinical Data on JR-171

Third quarter 2023 earnings released: EPS: JP¥20.89 (vs JP¥29.79 in 3Q 2022)

U.S. Fda Grants Rare Pediatric Disease Designation for JCR Pharmaceuticals Co., Ltd. Jr-141 for Mpsii

JCR Pharmaceuticals Co., Ltd. Appoints Yoh Ito as Senior Corporate Officer

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Announces Interim Dividend Payable on December 9, 2022; Provided Dividend Guidance for Fiscal 2023

Now 20% undervalued after recent price drop

JCR to Initiate Development of New Drug Candidate for Fucosidosis

Second quarter 2023 earnings: EPS and revenues miss analyst expectations